Bright Minds Biosciences Inc (DRUG) News

Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]

Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form SC 13D - General statement of acquisition of beneficial ownership

Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Bright Minds Announces Non-Brokered Private Placement Fully Subscribed by Management

Bright Minds Announces Non-Brokered Private Placement Fully Subscribed by Management Canada NewsWire VANCOUVER, BC, Dec. 6, 2023 /NOT FOR...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Bright Minds Biosciences Announces Positive qEEG (Quantitative Electroencephalogram) Data from its First-in-Human Phase 1 Study of Lead Compound, BMB-101

-- BMB-101 is a highly selective and potent 5-HT2C agonist being developed for the treatment of refractory...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Bright Minds Biosciences Announces Positive Topline Data for its First-in-Human Phase 1 Study of Lead Compound, BMB-101

-- BMB-101 is a highly selective and potent 5-HT2C agonist being developed for the treatment of refractory...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Bright Minds Announces Effective Date of Share Consolidation

VANCOUVER, British Columbia, July 11, 2023 (GLOBE NEWSWIRE) -- Bright Minds Biosciences Inc. (CSE: DRUG...

Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)

UNITED STATESSECURITIES AND EXCHANGE COMMISSIONWashington, D.C.  20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR...

Bright Minds Announces Proposed Share Consolidation

VANCOUVER, British Columbia, June 22, 2023 (GLOBE NEWSWIRE) -- Bright Minds Biosciences Inc. (CSE: DRUG...